Announcement no. 3/2026 Inside information Coloplast appoints Gavin Wood as new CEO The Coloplast Board of Directors is ...

Most recently, Wood served as company group chair of Johnson & Johnson MedTech EMEA. There, he oversaw a multi-billion-dollar ...

Recent share performance and valuation context Coloplast (CPSE:COLO B) has drawn investor attention after a series of weaker ...

Coloplast is a global leader in specialized intimate healthcare, with strong innovation, high margins, and a defensible moat in core segments. Despite a 20% share price drop, I see upside potential, ...

Coloplast announced it will acquire wound care product company Kerecis for $1.3 billion. The acquisition will give Coloplast an opportunity to “strategically strengthen [its] presence in the advanced ...

Coloplast is a leading global supplier of intimate healthcare products with a strong product portfolio and high market share. The company has a stable business model and benefits from demographic ...

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...

There’s something fishy about Coloplast’s latest megadeal—literally. The Danish medtech announced (PDF) plans on Friday to acquire Kerecis, which uses fish skin as the basis of its wound care products ...

The average one-year price target for Coloplast A (OTCPK:CLPBF) has been revised to $92.23 / share. This is a decrease of 11.54% from the prior estimate of $104.27 dated February 3, 2026. The price ...

Coloplast historically has introduced consistent innovation in its ostomy-care products, including different types of adhesives, one- and two-piece devices, and irrigation systems. Finally, we note ...

COPENHAGEN, July 7 (Reuters) - Coloplast (COLOb.CO), opens new tab has agreed to buy Iceland-based Kerecis, a biologic wound care firm that uses fish skin to develop tissue-transplant products, for up ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.